Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCB-420 vs Eylea in Neovascular Age-related Macular Degeneration
NCT04919096Phase 1Withdrawn
- Sponsor
- Clover Biopharmaceuticals
- Start
- Apr 2022
- Primary completion
- Sep 2022
- Modality
- Allosteric Modulators
01
Overview
Phase 1, randomised, double-blind trial of sonidegib in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Clover Biopharmaceuticals. Primary endpoint: Incidence of ocular and non-ocular adverse events. Planned start Apr 2022; status: withdrawn.
02
Drugs
sonidegib
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT04919096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04919096.